Trabectedin in ovarian cancer: could we expect more?
IOSI Oncology, San Giovanni Hospital, Bellinzona, Switzerland; Progetto Montabone, Fondazione IRCCS, National Cancer Institute, Milano, Italy. Electronic address: cristiana.sessa@eoc.ch.
C
C
Sessa
Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy.
M
M
D'Incalci
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D004149:Dioxoles / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D000077606:Trabectedin
D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin